Oppenheimer began coverage on shares of Organogenesis (NASDAQ:ORGO) in a research report report published on Wednesday, BenzingaRatingsTable reports. The brokerage issued an outperform rating and a $11.00 price objective on the stock.

Several other equities research analysts also recently issued reports on ORGO. SunTrust Banks initiated coverage on Organogenesis in a research note on Thursday, April 11th. They issued a buy rating and a $11.00 price objective for the company. BTIG Research initiated coverage on Organogenesis in a research note on Friday, April 12th. They issued a buy rating and a $12.00 price objective for the company.

Organogenesis stock traded up $0.12 during mid-day trading on Wednesday, hitting $7.95. The company’s stock had a trading volume of 16 shares, compared to its average volume of 114,175. Organogenesis has a 52-week low of $6.28 and a 52-week high of $310.90.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types.

Read More: What is the QQQ ETF?

Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.